Cargando…
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
BACKGROUND: The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at < 32(+0) weeks gestation is either imminent or threatened for the purpose of fetal neuroprotection. METHODS: Multiple decision tree models and probabilis...
Autores principales: | Bickford, Celeste D, Magee, Laura A, Mitton, Craig, Kruse, Marie, Synnes, Anne R, Sawchuck, Diane, Basso, Melanie, Senikas, Vyta M, von Dadelszen, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878233/ https://www.ncbi.nlm.nih.gov/pubmed/24350635 http://dx.doi.org/10.1186/1472-6963-13-527 |
Ejemplares similares
-
Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada
por: Teela, Katherine C., et al.
Publicado: (2015) -
MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada
por: De Silva, Dane A., et al.
Publicado: (2018) -
Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes
por: Houlihan, Sara, et al.
Publicado: (2016) -
Antenatal magnesium sulphate administration for fetal neuroprotection: a French national survey
por: Chollat, Clément, et al.
Publicado: (2017) -
Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India
por: Katageri, Geetanjali, et al.
Publicado: (2018)